Exciting Updates from Aligos Therapeutics
Aligos Therapeutics, Inc. (NASDAQ: ALGS), a biopharmaceutical company at the forefront of liver and viral disease therapies, has recently shared important developments through six preclinical presentations at the 2025 International HBV Meeting. This event, scheduled to take place from September 8 to 12, centers on groundbreaking strategies in the fight against hepatitis B virus (HBV) and hepatitis delta virus (HDV).
Showcasing Innovative Research
During the presentations, Aligos discussed advanced therapeutic prospects that tackle significant challenges faced by patients with liver and viral ailments. The research not only reflects the company's commitment to enhancing patient outcomes but also emphasizes its innovative strategies in developing next-generation therapies.
Focus on ALG-000184's Mechanism
One of the key highlights from the presentations includes insights into ALG-000184, a promising therapeutic candidate. Researchers are particularly excited about the direct effects of ALG-000184, which has shown potential in reducing HBV cccDNA in preclinical settings. This revelation aligns with clinical observations that indicated decreased HBV antigen levels in treated individuals.
New Strategies for HDV
Along with ALG-000184, Aligos is venturing into unexplored territories with its innovative ASO (antisense oligonucleotide) program aimed at HDV treatment. The preliminary research presented at the meeting reflects the ASO's unique ability to target and potentially eliminate the viral genome, marking a hopeful step toward an HDV cure.
Details of the Presentations
Below are some noteworthy presentations from the event:
Oral Presentations
- Paper #: 52
Title: The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
Presenter: Yannick Debing, PhD
Date/Time: September 11, 2025 - Paper #: 53
Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
Presenter: Julie Lucifora, PhD - Paper #: 2
Title: A Syrian hamster model of persistent HDV infection
Presenter: Elias Broeckhoven
Poster Presentations
- Paper #: 283
Title: Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro
Presenter: Hannah Vanrusselt - Paper #: 285
Title: Capsid assembly modulators bind and directly target HBeAg
Presenter: Jordi Verheyen - Paper #: 127
Title: PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells
Presenter: Vaclav Janovec, PhD
Aligos's Mission and Future Plans
Aligos Therapeutics continues to pursue its mission of providing innovative therapies for unmet medical needs in the realm of liver diseases. With its dedicated research team and robust pipeline, the company aims to make strides in treating chronic HBV infection and associated conditions. The progress showcased at the meeting exemplifies this commitment.
As the company moves forward, it remains focused on diligently developing its clinical candidates while pursuing options that could change the landscape of treatment for liver and viral diseases.
Frequently Asked Questions
What is Aligos Therapeutics known for?
Aligos Therapeutics is recognized for developing therapies aimed at liver and viral diseases, focusing on chronic hepatitis B and hepatitis delta virus.
What are the notable findings from the recent presentations?
The presentations highlighted promising results from ALG-000184 regarding HBV cccDNA reduction and an innovative ASO approach targeting HDV.
When is the International HBV Meeting?
The International HBV Meeting is being held from September 8 to September 12, 2025.
Who are some of the presenters at the meeting?
Notable presenters include Yannick Debing, PhD, and Julie Lucifora, PhD, who discussed their research findings on HBV and HDV.
How can I learn more about Aligos Therapeutics?
For more information, visit the Aligos Therapeutics website or follow them on their social media platforms.
